Renowned obstetric epidemiologist Lelia Duley, a trailblazer who transformed the treatment of pregnant women with groundbreaking research, has passed away at the age of 67.
Lelia's remarkable career was marked by numerous milestones, including designing large-scale trials that tested commonly used but under-evaluated treatments for pregnant women. Her most significant contribution came in 1995 when the results of the Collaborative Eclampsia trial, which she coordinated, revealed that magnesium sulphate was a more effective treatment than diazepam for eclampsia and significantly reduced mortality rates.
This seismic shift in medical practice led to an overnight change in standard care options worldwide, with the use of magnesium sulphate becoming the new norm. Her pioneering work not only improved patient outcomes but also saved countless lives.
Born in Oxford, Lelia's academic journey took her to Aberdeen University, where she studied medicine before embarking on a series of placements, including one in Israel. She began her research career as a house officer at various hospitals across the UK before becoming a Wellcome fellow and principal investigator for the eclampsia trial.
Throughout her illustrious career, Lelia held numerous positions, including deputy director of the UK Cochrane Centre and professor of obstetric epidemiology at Leeds University. Her final role was as professor of clinical trials research at Nottingham University, where she specialized in trial design.
Lelia's impact extended beyond her professional sphere. She led her researchers with humility, charm, and humour, valuing people, listening to their concerns, and striving for evidence-based solutions. Even in the face of chronic illness, Lelia continued to contribute to patient-led charities, such as CLL Support, and benefited from a buddying facility that connected her with others living with leukemia.
Lelia is survived by her husband, children, and two brothers, leaving behind an indelible mark on the medical community and countless lives touched by her selfless dedication.
Lelia's remarkable career was marked by numerous milestones, including designing large-scale trials that tested commonly used but under-evaluated treatments for pregnant women. Her most significant contribution came in 1995 when the results of the Collaborative Eclampsia trial, which she coordinated, revealed that magnesium sulphate was a more effective treatment than diazepam for eclampsia and significantly reduced mortality rates.
This seismic shift in medical practice led to an overnight change in standard care options worldwide, with the use of magnesium sulphate becoming the new norm. Her pioneering work not only improved patient outcomes but also saved countless lives.
Born in Oxford, Lelia's academic journey took her to Aberdeen University, where she studied medicine before embarking on a series of placements, including one in Israel. She began her research career as a house officer at various hospitals across the UK before becoming a Wellcome fellow and principal investigator for the eclampsia trial.
Throughout her illustrious career, Lelia held numerous positions, including deputy director of the UK Cochrane Centre and professor of obstetric epidemiology at Leeds University. Her final role was as professor of clinical trials research at Nottingham University, where she specialized in trial design.
Lelia's impact extended beyond her professional sphere. She led her researchers with humility, charm, and humour, valuing people, listening to their concerns, and striving for evidence-based solutions. Even in the face of chronic illness, Lelia continued to contribute to patient-led charities, such as CLL Support, and benefited from a buddying facility that connected her with others living with leukemia.
Lelia is survived by her husband, children, and two brothers, leaving behind an indelible mark on the medical community and countless lives touched by her selfless dedication.